N-methyl-D-aspartic acid receptor modulators
AssigneeEmory Univeristy
InventorsDennis Liotta, Stephen F. Traynelis, David Menaldino, Matthew Epplin
Life of this patent
Estimating the term…
Abstract
A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.
Claims18
A compound of Formula (I) or a salt thereof,
- wherein R1 is H, alkyl, alkoxy, aryl, heteroaryl, halogen, hydroxy, amide, amine, alkylamino, aminoalkyl, nitrile, nitro, or OCF3;
- R2 and R2′ are each, individually H, or together form ═O, ═S, or ═NH;
- R3 is aryl or heteroaryl, optionally substituted with R5;
- R4 and R4′ are each, individually H, or together form ═O, ═S, or ═NH;
- Ring C is a five or six membered heteroaryl or heterocyclyl ring;
- R5, in each occurrence, is independently H, alkyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, alkoxy, amine, amide, halogen, hydroxy, nitrile, nitro, or CF3;
- X is O;
- Y is N, C, or CH;
- Z, in each occurrence, is independently CH, CH2, N, NH, S, or O;
- and
- the dashed bond, represented by , is a single bond.
Dependencies are inferred from the claim text.